Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML

Poster Session
Presenter: Vinod Pullarkat, MD, MRCP
Abstract Number: 7026
Presented: June 4, 2021
Track: Hematologic Malignancies
Disclosures: View Disclosures
© 2022 American Society of Clinical Oncology (ASCO®). All Rights Reserved.
Share:
Share on facebook
Share on twitter
Share on linkedin

Expert Interviews That Reference This Abstract

Expert Interview

Hematologic Malignancies – Expert Insights

Interviewee: Charles Craddock, CBE, FRCP, FRCPath, DPhil
Professor Craddock discusses three hematology-oncology abstracts from the ASCO21 Annual Meeting reporting on the use of letermovir to prevent cytomegalovirus reactions in allogeneic stem cell transplant recipients with graft versus host disease (abstract 7004), first-line asparcytarabine in acute myeloid leukemia patients unfit for standard chemotherapy, and the initial results from the V-FAST trial of CPX-351 plus targeted agents for newly diagnosed acute myeloid leukemia.

Other Hematologic Malignancies Content

Expert Interview

Hematologic Malignancies – Expert Insights

Professor Craddock discusses three hematology-oncology abstracts from the ASCO21 Annual Meeting reporting on the use of letermovir to prevent cytomegalovirus reactions in allogeneic stem cell transplant recipients with graft versus host disease (abstract 7004), first-line asparcytarabine in acute myeloid leukemia patients unfit for standard chemotherapy, and the initial results from the V-FAST trial of CPX-351 plus targeted agents for newly diagnosed acute myeloid leukemia.
Interviewee: Charles Craddock, CBE, FRCP, FRCPath, DPhil
Interview Date: June 8, 2021
Expert Interview

Hematologic Malignancies – Expert Insights

Dr Berdeja discusses ASCO21 highlights for multiple myeloma, including updated results from the phase III ANDROMEDA study (abstract 8003), interim analysis of CASSIOPEIA, daratumumab maintenance vs observation (abstract 8004), updated results on ciltacabtagene autoleucel CAR-T therapy from CARTITUDE-1 (abstract 8005), results of a trial with bi-specific agent elranatamab (abstract 8006) and study of bi-specific agent teclistamab (abstract 8007) and of talquetamab in relapsed/refractory MM (abstract 8008) and updated results from the pivotal KarMMa study (abstract 8016).
Interviewee: Jesus G. Berdeja, MD
Interview Date: June 8, 2021
Expert Interview

Hematologic Malignancies – Expert Insights

Dr Shah discusses her ASCO21 highlights for multiple myeloma, including interim analysis of CASSIOPEIA, part 2-- daratumumab maintenance vs observation (abstract 8004), updated results on ciltacabtagene autoleucel CAR-T therapy from CARTITUDE-1 (abstract 8005), and results of recommended phase 2 dose in the first in-human phase 1 study of teclistamab (abstract 8007) and of talquetamab in relapsed/refractory MM (abstract 8008).
Interviewee: Nina Shah, MD
Interview Date: June 8, 2021
Oral Abstract Session

Letermovir prophylaxis and cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients with graft versus host disease

Presenter: Delaney Wolfe
Presentation Date: June 4, 2021
Abstract Number: 7004
Oral Abstract Session

Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy

Presenter: Jessica K. Altman, MD
Presentation Date: June 4, 2021
Abstract Number: 7007
Oral Abstract Session

Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study

Presenter: Efstathios Kastritis, MD
Presentation Date: June 8, 2021
Abstract Number: 8003
Oral Abstract Session

Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2

Presenter: Philippe Moreau, MD
Presentation Date: June 8, 2021
Abstract Number: 8004
Oral Abstract Session

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1

Presenter: Saad Zafar Usmani, FACP, MBA, MD
Presentation Date: June 8, 2021
Abstract Number: 8005
Oral Abstract Session

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)

Presenter: Nizar J. Bahlis, MD
Presentation Date: June 8, 2021
Abstract Number: 8006
Oral Abstract Session

Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM)

Presenter: Amrita Y. Krishnan, MD
Presentation Date: June 8, 2021
Abstract Number: 8007
We'd love your feedback!
We'd love your feedback!

Welcome to ASCO Direct™

2021 Annual Meeting Highlights

Expert insights into key ASCO21 data that will impact clinical practice and patient care plus complimentary access to 50 official ASCO video presentations and downloadable slides, picked by our Experts.

ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)

This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare